Compare Nuwellis Inc (NUWE) vs Wendys Co (WEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs Wendys Co — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while Wendys Co trades at $6.22 (market cap $1.19B). The key difference: Wendys Co is far larger — about 540.9× Nuwellis Inc's market cap, and Wendys Co pays a 4.49% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and Wendys Co for 77 Days on average.
| NUWE | WEN | |
|---|---|---|
Market Cap | $2.20M | $1.19B |
Volume | 121,544 | 5,622,905 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $9.33 |
52-Week Low | $0.68 | $6.10 |
Typical Hold Time | 26 Days | 77 Days |
Enterprise Value | -$1.52M | $4.92B |
Dividend Yield | — | 4.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
Wendy's stock (WEN) trades at $6.11, down 0.81% recently, with a bearish technical signal and oversold RSI indicators. The company shows mixed fundamentals: it has beaten earnings estimates for three consecutive quarters but faces declining net income margins and high debt levels. Recent news highlights challenges, including a major franchisee bankruptcy and same-store sales declines, contributing to negative sentiment.
The outlook for WEN is cautious. While its low P/E ratio of 9.25 and consistent earnings beats offer value, risks from franchisee instability, competitive pressures, and declining profitability weigh on growth. Analyst consensus is a 'Hold' with a $7.58 price target, suggesting limited upside amid operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →
